Cost-utility analysis of the use of a wearable cardioverter defibrillator (LifeVest®) versus standard of care in the prevention of sudden cardiac death in patients after myocardial infarction
Przemysław Mitkowski(Poznan University of Medical Sciences), Dominik Golicki, Andrzej Przybylski(University of Rzeszów), Iwona Dobrowolska(Mostostal Warszawa (Poland)), Katarzyna Młyńczak(Mostostal Warszawa (Poland)), Andrzej Ząbek(Jagiellonian University), Łukasz Szumowski(Institute of Cardiology), Maciej Kempa(Gdańsk Medical University), Marek Gierlotka(University of Opole), Jerzy Krzysztof Wranicz(Medical University of Lodz), Michał M. Farkowski(Institute of Cardiology), Agnieszka Pawlak(Ministry of Interior), Jarosław Kaźmierczak, Maciej Niewada(Medical University of Warsaw), Marcin Michalak(Medical University of Silesia), Robert Gil(Ministry of Interior and Administration), Paweł Ptaszyński(Medical University of Lodz), Maciej Sterliński(Institute of Cardiology), Adam Sokal(Silesian Center for Heart Disease), Marcin Czech(Warsaw University of Technology), Mateusz Tajstra(Silesian Center for Heart Disease), Adam Wojtaszczyk(Medical University of Lodz), Adam Witkowski(Institute of Cardiology), Oskar Kowalski(Silesian Center for Heart Disease)
Cited by 1
Related Papers
European Society of Cardiology: cardiovascular disease statistics 2021
|European Heart Journal|2021|1.1k
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889